Direxion Daily S&P Biotech Bull 3X Shares(LABU)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$172
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for LABU

11/20/2026: LABU (1-star) is currently NOT-A-BUY. Pass it for now.

LABU provides triple daily leveraged exposure to the S&P Biotechnology Select Industry Index via financial derivatives. Its primary strengths lie in its high liquidity, tight trading spreads, and dominance among tactical trading products. It serves as an aggressive tool for short-term momentum strategies rather than a long-term core holding. Key risks include severe compounding decay over time, high expense ratios, and extreme sector volatility driven by binary clinical events. It suits active traders who closely monitor positions and manage risk on a daily basis.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitDue to daily rebalancing and leverage decay, it is unsuitable for long-term growth investing.
Momentum investorStrong fit while signal remains positiveIt offers aggressive triple exposure ideal for short-term tactical momentum plays during strong sector rallies.
Value investorWeak fitLeveraged synthetic exposure ignores traditional fundamental valuation and long-term holding principles.
Dividend/Income investorWeak fitThe fund does not distribute meaningful dividends and focuses purely on daily capital movement.
Low-risk investorWeak fitThe extreme volatility and risk of total capital loss conflict entirely with conservative objectives.

Investor Profile

Ideal Investor Profile

Active tactical traders, day traders, and sophisticated momentum investors looking for short-term, high-beta exposure to the biotechnology sector.

Suitability

Strictly suited for short-term intraday or multi-day trading, entirely unsuited for buy-and-hold long-term investing due to volatility decay.

Risk Profile

Risk factorLevelWhy it matters
VolatilityHighDaily 3x leverage amplifies underlying biotech stock fluctuations into extreme portfolio swings.
Market riskHighThe biotech sector is inherently speculative and heavily impacted by clinical data and regulatory decisions.
ConcentrationHighThe fund targets a single industry sector, exposing investors to localized structural downturns.
Tracking/expenseMedium / highCompounding and high expense ratios cause long-term performance to deviate significantly from 3x the index.
LiquidityLowDespite strong fund-level trading volume, underlying constituent liquidity can strain severe market events.
Business/sector qualityHighMany constituents are pre-revenue clinical-stage companies carrying binary operational risks.

Sector & Industry Intelligence

This fund is not assigned to one sector.

Risk Analysis

Volatility

LABU exhibits exceptionally high historical volatility due to its 3x daily leverage multiplier applied to an already volatile biotech index.

Market Risk

Carries acute exposure to adverse clinical updates, regulatory changes, and broader risk-off equity corrections.

What the ETF Owns

Exposure TypeExposureWeight (%)Retail Investor Read
DerivativesS&P Biotechnology Select Industry Index — seeks 3x daily leverage return100Provides triple daily leveraged exposure to the performance of the US biotech sector index through swap agreements and financial derivatives.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type ETF
Historic Profit -3.61%
Avg. Invested days 25
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
ETF Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026
Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.